Michael Gelband’s Niagen Bioscience NAGE Stock Holding History

Michael Gelband’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$174K	Buy	54,661 +32,539	+147%	+$132K	﹤0.01%	1432
2026 Q1	$97.6K	Buy	+22,122	New	+$119K	﹤0.01%	1437
2024 Q4	–	Sell	-39,900	Closed	-$146K	–	2166
2024 Q3	$146K	Buy	+39,900	New	+$126K	﹤0.01%	1486
2024 Q2	–	Sell	-20,930	Closed	-$73K	–	2076
2024 Q1	$73K	Buy	+20,930	New	+$38.7K	﹤0.01%	1426
2021 Q3	–	Sell	-12,792	Closed	-$126K	–	2748
2021 Q2	$126K	Sell	12,792 -19,977	-61%	-$174K	﹤0.01%	2100
2021 Q1	$306K	Buy	+32,769	New	+$260K	﹤0.01%	1657

Other funds holding NAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Michael Gelband's NAGE Position: Q2 2026 in Review

Michael Gelband increased its Niagen Bioscience (NAGE) stake by 147% in Q2 2026, buying an estimated $132K and bringing the position to 54,661 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #1432.

Michael Gelband first reported a position in NAGE in Q1 2021 and has held it in 6 quarters since. The position peaked at $306K in Q1 2021. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

Michael Gelband held 54,661 shares of Niagen Bioscience worth $174K as of Q2 2026.
Michael Gelband bought 32,539 Niagen Bioscience shares in Q2 2026, an estimated $132K.
Niagen Bioscience made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1432 holding.
Michael Gelband first reported a position in Niagen Bioscience in Q1 2021 and has held it in 6 quarters since.
Michael Gelband's Niagen Bioscience position peaked at $306K in Q1 2021.
139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.